جست‌وجوی استاد و پژوهشگر

Matthias Mannمشاهده پروفایل

استاد

• Mass Spectrometry
• Proteomics
• Systems Biology
• +۶ مورد دیگر

Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.

Anja Liekfeldمشاهده پروفایل

استاد مدعو

• Ophthalmology
• Optical Device Technology
• Refractive Surgery
• +۳ مورد دیگر

Anja Liekfeld serves as Adjunct Professor of Ophthalmic Optics/Optical Device Technology at Brandenburg University of Technology since 2018 while concurrently holding the position of Chief Physician at Klinikum Ernst von Bergmann's Department of Ophthalmology in Potsdam since 2009. Her dual roles bridge academic research in optical engineering with clinical ophthalmology practice, focusing on technological advancements for eye care delivery. Her educational foundation includes medical studies at Essen and Berlin Universities (1986-1992), state examination (1992), ophthalmology residency at Charité (1994-1997), specialist certification (1997), doctoral degree magna cum laude (1997), and habilitation on capsular bag models for cataract research (2007). Liekfeld's research centers on optical properties of intraocular lenses, clinical applications of medical devices in ophthalmology, refractive surgery techniques (laser and IOLs), cataract surgery technologies, glaucoma diagnostics/therapy, and gerontological ophthalmology. Her work emphasizes translating engineering principles into clinical solutions for complex vision correction challenges. Over 25 years of publications reveal evolving expertise from molecular glaucoma research to advanced IOL development. Recent work focuses on multifocal/toric lenses, dysphotopsia analysis, and visual outcomes measurement, demonstrating consistent innovation at the optics-clinical interface with practical applications for patient care. Her accolades include: DOG/SFO Travel Grant (2000) DGII Best Presentation Award (2008) DOC Gold Medal (2011) Focus Magazine Top Doctor (2013-2021) Stern Magazine Top Doctor (2022) As an educator, she trains surgical assistants, diet technicians, and operating room staff while teaching ophthalmology to visually impaired pedagogy students at Humboldt University. She conducts international wet labs for surgeons and optometrists, serves on editorial boards for Concept and Karger Kompass Ophthalmologie, and reviews for major ophthalmology journals. Active in professional societies including DGII, ESCRS, DOG, BBAG, and BDOC, she chairs Brandenburg's Ophthalmology Examination Board since 2021 and serves on the board of Die Augenchirurginnen e.V. Her research utilizes human capsular bag models for cataract studies and maintains focus on improving optical device performance in clinical settings.

Moritz Rossnerمشاهده پروفایل

استاد

• Molecular Neurobiology
• Behavioral Neurobiology
• Mouse Genetics
• +۷ مورد دیگر

Professor Moritz Rossner serves as Head of the Department of Molecular and Behavioral Neurobiology at the Department of Psychiatry and Psychotherapy, Faculty of Medicine, Ludwig-Maximilians-Universität München (LMU). His research integrates molecular and behavioral approaches to understand the neurobiological underpinnings of psychiatric disorders, particularly schizophrenia and bipolar disorder. Rossner's research interests focus on molecular neurobiology and behavioral analysis using mouse models. His laboratory employs advanced techniques including mouse genetics , behavioral phenotyping , biosensors , next-generation sequencing , and transcriptomics to investigate psychiatric risk genes and pathways. His work bridges cellular and molecular mechanisms with behavioral outcomes, particularly in schizophrenia and bipolar disorder research. Analysis of Rossner's 15 most recent publications (2025) reveals a strong focus on precision psychiatry , neuroimaging biomarkers , and genetic mechanisms underlying psychiatric disorders. His research increasingly incorporates multimodal approaches combining neuroimaging, genomics, and clinical phenotyping to develop biologically informed diagnostic and treatment frameworks. Key themes include blood-brain barrier dysfunction in schizophrenia, inflammatory contributions to symptom severity, and pathway-specific polygenic scores for treatment prediction. Rossner leads the Molecular & Behavioural Neurobiology working group at LMU's Department of Psychiatry and Psychotherapy, which includes specialized units like the Mouse Behavioral Unit. His research program appears well-funded through multiple collaborative projects focused on understanding the molecular basis of psychiatric disorders and developing novel therapeutic approaches.

Andreas Faustمشاهده پروفایل

دانشیار

• organic chemistry
• medicinal chemistry
• radiopharmaceutical chemistry
• +۷ مورد دیگر

Privatdozent Dr. Andreas Faust is a leading researcher at the European Institute for Molecular Imaging (EIMI) at the University of Münster, where he heads the Chemical Targeting Lab. His work focuses on developing innovative imaging agents for medical diagnostics, particularly in radiopharmaceutical chemistry and molecular imaging. He maintains strong affiliations with the Department of Nuclear Medicine at the University Hospital Münster and participates in the "Cells in Motion" excellence cluster, contributing to cutting-edge research at the intersection of chemistry, medicine, and imaging technology. Dr. Faust completed his chemistry studies at the University of Münster, earning his Diploma in 1999, followed by his doctoral degree (Dr. rer. nat.) in 2003 with research on artificial caffeine receptors. His academic journey continued with positions at the Department of Organic Chemistry and the Department of Nuclear Medicine before becoming head of the chemistry group at EIMI in 2011. Dr. Faust's research centers on organic and medicinal chemistry with specialization in radiopharmaceutical chemistry . His team develops novel tracers for diagnostic molecular imaging using positron emission tomography (PET), single-photon emission computed tomography (SPECT), optical imaging, and photoacoustic imaging. A significant portion of his work focuses on creating specific ligands for the alarmins S100A8/S100A9 and bacteria-specific tracers based on complex carbohydrates or siderophores. His research has important applications in inflammation imaging, infection diagnostics, and cancer theranostics, with emphasis on improving metabolic stability and target specificity of imaging agents. His publication record demonstrates consistent contributions to molecular imaging, with recent work emphasizing bacteria-specific PET tracers, inflammation imaging targeting S100 proteins, and novel optical imaging probes. The research shows a clear trajectory toward developing clinically applicable imaging agents with improved specificity and metabolic stability, particularly in the areas of infection diagnostics and inflammation monitoring. 2017: Best Poster Award at Symposium "Molecular Imaging Agents in Medicine," Groningen 2009: Young Investigator Award at Deutscher Röntgenkongress, Berlin 2005: Best Scientific Poster Award at 4th Annual Meeting of the Society of Molecular Imaging, Köln Dr. Faust leads multiple significant research projects, including as Coordinator of a project on immune cell distribution imaging (2019-2024) and as Principal Investigator for CRC-project A03 "Targeting of S100A8/A9 for imaging of inflammatory disorders" and research on vascular graft infections (both 2021-2024). His Chemical Targeting Lab comprises a multidisciplinary team working at the intersection of chemistry, microbiology, and medical imaging, securing substantial funding from the Innovative Medicines Initiative and DFG Collaborative Research Centre. The Chemical Targeting Lab maintains state-of-the-art facilities for chemical synthesis, radiochemistry, and biological testing. The lab collaborates extensively with microbiologists, clinicians, and imaging specialists to translate basic research into clinical applications. Current research directions include optimizing bacterial imaging probes for clinical diagnostics and developing new inflammation-specific tracers for early disease detection, with particular focus on S100A9-targeted imaging and siderophore-based bacterial detection systems.

• Neuroscience
• Neuroimmunology
• Epigenetics
• +۳ مورد دیگر

Anne Schaefer is a Full Professor with Tenure at the Mount Sinai School of Medicine, currently serving as Managing Director at the Max Planck Institute for Biology of Ageing in Cologne, Germany. She co-directs the Center for Glial Biology within the Friedman Brain Institute, focusing on neuroscience and psychiatry. Education: Charité University Berlin (MD/PhD), Johannes Gutenberg University Mainz (undergraduate) Research Interests: Schaefer’s work bridges neuroscience , neuroimmunology , and epigenetics , with a primary focus on microglial biology, neuronal activity regulation, and mechanisms underlying neurodegeneration. Her studies explore how microglia interact with neurons to maintain brain homeostasis and drive plasticity. Scientific Awards: Max Planck Sabbatical Award (2019) Inaugural NINDS Landis Award for Outstanding Mentorship (2018) NIH Director’s New Innovator Award (2012) Kavli Frontiers in Science Fellow (2014) German Research Foundation DFG Research Fellowship (2006–2008) Summa cum laude, Charité University Berlin (2004) Grants & Funding: Schaefer has secured significant third-party funding, including an ERC Synergy Grant (2021–2027) for the project "Micro-'COPS' - Microglia-control of physiological brain states." Labs & Teams: She leads a research team at the Max Planck Institute for Biology of Ageing and collaborates closely with the Center for Glial Biology at Mount Sinai, where she has held leadership roles since 2017.

Felix Herbertمشاهده پروفایل

پژوهشگر ارشد

• International Law
• Public International Law
• Prohibition of the Use of Force
• +۳ مورد دیگر

Felix Herbert is a Research Fellow at the Max Planck Institute for Comparative Public Law and International Law (MPIL) in Heidelberg, Germany, where he has been working since January 2021. He also serves as a Lecturer at the University of Heidelberg's Faculty of Law since 2024 and as Associate Editor for the Max Planck Encyclopedia of Public International Law since 2025. In April 2025, he began a legal clerkship (Rechtsreferendariat) at the Heidelberg Regional Court as part of his German legal education path. Herbert's research focuses primarily on the prohibition of the use of force under international law and peremptory norms (ius cogens), with significant scholarly contributions analyzing these principles in the context of Russia's war against Ukraine. His dissertation project examines The Prohibition of the Use of Force as a Peremptory Norm of General International Law (ius cogens) . His work demonstrates how fundamental principles of international law apply to contemporary conflicts and challenges in global security. Herbert's publications reveal a strong emphasis on the practical application of international legal principles to current geopolitical conflicts, particularly examining the Russia-Ukraine war through the lens of ius cogens. His scholarship bridges theoretical international law with pressing real-world security challenges, contributing significantly to ongoing debates about the enforcement of fundamental legal norms during armed conflicts. Otto Schmidt Prize for the Promotion of the Europeanization and Internationalization of Law (2nd Prize, December 2024) for his contribution on ius cogens and Russia's war against Ukraine As an educator, Herbert has taught Working Groups on International Law at the University of Heidelberg since the Winter Semester 2021/22 and has served as a coach for the Heidelberg Jessup Moot Court teams. He has also been a judge for the Philip C. Jessup International Law Moot Court Competition since 2022. Additionally, he serves as the Environmental Officer for the MPIL, focusing on sustainability initiatives within the institute's operations.

• Neuro-oncology
• Neuropathology
• Glioblastoma
• +۳ مورد دیگر

Professor Patrick Harter is a faculty member at the Institute of Neuropathology, Ludwig Maximilian University of Munich (LMU), where he leads research in neuro-oncology and molecular diagnostics of CNS tumors. His work focuses on glioblastoma, meningioma, and brain metastasis, with emphasis on epigenetic mechanisms like DNA methylation and metabolic adaptations in the tumor microenvironment. Research interests span: Molecular classification of brain tumors using DNA methylation profiling Therapeutic targeting of BRAF/MEK and PI3K/Akt/mTOR pathways Role of hypoxia and metabolic plasticity in treatment resistance Liquid biopsy development for non-invasive tumor monitoring His recent publications demonstrate a strong trend toward integrating epigenetic, metabolic, and immunotherapeutic approaches. Articles frequently explore: Novel biomarkers for tumor grading and prognosis Mechanisms of therapy resistance in gliomas Impact of tumor microenvironment on metastasis

Charlotte Kloftمشاهده پروفایل

استاد

• Pharmacometrics
• Computational Disease Modeling
• Therapeutic Drug Monitoring
• +۶ مورد دیگر

Professor Charlotte Kloft is Head of the Department of Clinical Pharmacy & Biochemistry at the Institute of Pharmacy, Free University of Berlin since 2011, and spokesperson for the interdisciplinary Graduate Research Training Program PharMetrX 'Pharmacometrics and Computational Disease Modelling' since 2008. She previously served as Professor and Head of the Department of Clinical Pharmacy at Martin-Luther-University Halle-Wittenberg (2005-2011) and as Scientific Assistant/Senior Assistant at Freie Universität Berlin (1999-2005). Her academic credentials include a habilitation in Clinical Pharmacy from Freie Universität Berlin (2003) and a Dr. rer. nat. (summa cum laude) from the same institution (1997). She earned her license as a pharmacist in 1992 after completing pharmacy studies at Johannes Gutenberg-University, Mainz (1987-1991). Professor Kloft's research focuses on pharmacometrics, computational disease modeling, and therapeutic drug monitoring across multiple therapeutic areas. Her work bridges pharmaceutical sciences with clinical practice, with particular emphasis on personalized dosing strategies for oncology, antimicrobial resistance, and inflammatory bowel diseases. She has pioneered research in optimizing drug dosing through pharmacokinetic/pharmacodynamic modeling, with applications in both antibiotic and cancer therapies. Her recent publications demonstrate a strong evolution toward integrating advanced computational approaches with clinical pharmacology, including machine learning applications in pharmacometrics, personalized dosing strategies for biologics during pregnancy, and developing nationwide infrastructure for therapeutic drug monitoring in cancer therapy through the ON-TARGET study. Academic Center of Excellence of Pharsight (now Certara), USA (since 2000) Habilitationsreisestipendium of Dr. August and Dr. Anni Lesmüller-Stiftung (2002) Ernst-Reuter-Preis of Ernst-Reuter-Gesellschaft (1998) Joachim-Tiburtius-Preis of Berlin Senate (1998) Young Investigator Award of EORTC-PAMM (1997) Professor Kloft has successfully supervised numerous doctoral students whose research spans diverse areas including CAR-T cell therapy, antimicrobial resistance, inflammatory bowel disease treatment optimization, and pharmacokinetic modeling of novel therapeutic agents. Her research group has secured significant funding for projects including GlobalResist, ON-TARGET, ABIMMUNE, COMBINATORIALS, and TAIN. She leads a vibrant research ecosystem at the Free University of Berlin with strong collaborations across Europe and internationally, maintaining state-of-the-art laboratory facilities including Biosafety Level 2 certified labs for infectious disease research.

Sebastian Schlückerمشاهده پروفایل

استاد

• Surface-Enhanced Raman Spectroscopy (SERS)
• Plasmonics
• Nanophotonics
• +۱۲ مورد دیگر

Prof. Dr. Sebastian Schlücker is a full professor in the Department of Physical Chemistry at the University of Duisburg-Essen , where he leads the Molecular Biophotonics and Nanodiagnostics research group within the Faculty of Chemistry. He is actively engaged in research, teaching, and academic leadership, with a strong focus on advanced spectroscopic techniques for biomedical and analytical applications. His research interests lie at the intersection of nanophotonics, plasmonics, and bioanalytical chemistry . Key areas include surface-enhanced Raman spectroscopy (SERS) , single-particle spectroscopy , laser diagnostics , and the design of functionalized metal colloids for biosensing and tumor diagnostics. He emphasizes a theory-guided approach combining simulation and experiment to tailor nanoparticle properties. His recent publications (2023–2025) reflect a strong trend toward quantitative, label-free molecular diagnostics , point-of-care testing , and in situ monitoring of catalytic and biological processes . The work spans fundamental plasmonics to clinical applications, particularly in cancer detection and immunoassays using SERS nanotags. International Raman Innovation Prize He mentors students and researchers, supervises theses, and collaborates widely across disciplines. His group develops advanced instrumentation, including portable SERS readers , fs-laser laboratories , and automated nanoparticle synthesis systems (e.g., BONAPARTE robot). He teaches master’s courses such as NanoBioPhotonics and Optical Spectroscopy , and is involved in STEM outreach.

Jochen Wolfمشاهده پروفایل

استاد

• Evolutionary Biology
• Speciation Genomics
• Genome Evolution
• +۷ مورد دیگر

Jochen Wolf is Chair of the Evolutionary Biology Division at Ludwig-Maximilians-Universität München (LMU) and a Max Planck Fellow of the Max Planck Institute for Biological Intelligence since 2022. His research integrates evolutionary biology, genomics, and ecology to address fundamental questions about speciation, adaptation, and biodiversity across multiple biological systems. Dr. Wolf's research program applies an integrative approach to understand microevolutionary processes and genetic mechanisms underlying species divergence. His work combines large-scale genomic analyses with laboratory and field experiments to characterize genomic divergence across populations and species. Key empirical systems include natural populations of birds (particularly corvids, swallows, and cuckoos), marine mammals (pinnipeds and killer whales), plant communities, and experimental evolution in fission yeast. His research spans multiple scales from immediate microevolutionary processes to broader evolutionary patterns across time. His recent publications reveal a sophisticated integration of genomic, epigenetic, and ecological perspectives. A notable trend shows increasing focus on structural genomic variation, chromosomal rearrangements, and epigenetic mechanisms as drivers of evolutionary processes. His work demonstrates how these molecular mechanisms interact with ecological factors to shape patterns of biodiversity and adaptation. Dr. Wolf's research has gained significant recognition through publications in top-tier journals including Nature, Science, and Nature Ecology & Evolution. His groundbreaking studies on crow hybrid zones, killer whale ecotypes, and experimental evolution of speciation have been featured in prominent media outlets such as The New Yorker, The Guardian, Scientific American, and Der Spiegel, demonstrating the broad impact of his work. As Principal Investigator, Dr. Wolf actively mentors doctoral students and postdoctoral researchers, fostering the next generation of evolutionary biologists. His lab maintains strong international collaborations, particularly through affiliations with SciLifeLab in Uppsala. Research in his group is supported by multiple funding sources including German Research Foundation grants and European Union programs, enabling both fundamental research and applications to conservation biology. The Wolf lab operates within LMU's Division of Evolutionary Biology, which provides access to state-of-the-art facilities including the Leibniz Supercomputing Centre. The lab maintains strong connections with the Max Planck Institute for Biological Intelligence and SciLifeLab in Uppsala, creating a rich collaborative environment for interdisciplinary research in evolutionary genomics. This network enables comprehensive studies spanning from molecular mechanisms to ecological and evolutionary consequences across diverse biological systems.

Martin A. Kriegelمشاهده پروفایل

استاد

• Host-microbiota interactions in autoimmunity
• Gut commensal translocation mechanisms
• Microbiota-induced immune cell migration
• +۵ مورد دیگر

Univ.-Prof. Dr. med. Martin A. Kriegel serves as full Professor and Department Head of the Department of Translational Rheumatology and Immunology at the Institute of Musculoskeletal Medicine, University of Münster, while maintaining an active laboratory at Yale School of Medicine. He leads the Section for Rheumatology and Clinical Immunology (SRKI) at Medical Clinic D, where his team integrates clinical care with cutting-edge microbiome research. His department operates from Röntgenstraße 21 and Von-Esmarch-Str. 54 in Münster, Germany, with extensive collaborations including the "Cells in Motion" research initiative and the CiM-IMPRS graduate program. Dr. Kriegel's research program focuses on the critical interface between host immunity and microbiota, particularly investigating how gut commensals translocate to host tissues and trigger autoimmune responses. His laboratory pioneered the discovery that specific pathobionts like Enterococcus gallinarum and certain Lactobacillus strains can translocate from the gut to mesenteric lymph nodes, liver, and other sites, driving autoimmune responses through molecular mimicry of human autoantigens. His work has established fundamental mechanisms by which microbiota influence rheumatic diseases, cutaneous autoimmunity, and cancer immunology, with particular emphasis on Ro60 autoantigen mimicry, TLR7-dependent pathways, and diet-microbiome interactions. The laboratory employs advanced techniques including gnotobiotic mouse models, humanized systems, and detailed molecular characterization of host-pathobiont interactions. Analysis of Dr. Kriegel's publication record reveals a consistent trajectory of high-impact research connecting microbiome dynamics to autoimmune pathogenesis. His most recent work (2023-2025) demonstrates increasingly sophisticated understanding of how specific bacterial strains influence disease phenotypes across multiple autoimmune conditions, with notable advances in identifying shared microbiome signatures across lupus and inflammatory bowel disease. The publications show progressive refinement from initial observations of microbial translocation to detailed mechanistic insights into tryptophan catabolism pathways, structural basis of molecular mimicry, and diet-sensitive microbial triggers. Dr. Kriegel's scientific recognition includes US Patent No. 11,058,756 B2 for compositions treating autoimmune diseases by reducing enterococcus, reflecting the translational potential of his research. His laboratory receives substantial funding, most notably a $3 million award from the Lupus Research Alliance for the TransLuMi project investigating gut pathobiont translocation in systemic lupus erythematosus. As an educator and mentor, Dr. Kriegel directs a substantial research team including multiple postdocs (Drs. Marcia Pereira, Nathalie Becker), PhD candidates (Anna Brinkhege, Carina Brune, Helen Fuhrmann), and laboratory specialists. He participates in the CiM-IMPRS graduate program and supervises medical students through the MedK program. His laboratory currently manages multiple significant research projects including: (A) intestinal wall permeability and pathobiont translocation in autoimmunity; (B) diet-environment-microbiome interactions; (C) microbiota disruption of immunological tolerance; and (D) microbiome roles in lymphoma development. The Kriegel laboratory maintains state-of-the-art facilities at both Münster and Yale, with specialized capabilities in gnotobiotic research, microbiome analysis, and immune profiling. His team collaborates with international partners including Dr. Eran Elinav at Weizmann Institute, Dr. Nissan Yissachar at Bar-Ilan University, Prof. George Tsokos at Harvard, and Prof. Ilana Brito at Cornell University. The laboratory's website (https://www.medizin.uni-muenster.de/mikrobiom/startseite/) details ongoing projects and research opportunities.

Rainer Böckmannمشاهده پروفایل

استاد

• Computational Biology
• Theoretical Biophysics
• Membrane Biophysics
• +۷ مورد دیگر

Rainer Böckmann is a Professor of Computational Biology in the Department of Biology at Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Germany, where he leads the Group for Theoretical and Computational Membrane Biophysics. His research integrates molecular dynamics simulations with biophysical analysis to study membrane structure, dynamics, and function. Research Interests: His work focuses on computational biophysics, particularly lipid bilayers, membrane proteins, molecular dynamics, and structural bioinformatics. He investigates how lipid composition, cholesterol, and embedded peptides influence membrane organization, curvature, and permeability, with applications in antimicrobial strategies and mRNA vaccine delivery systems. Recent Research Trends: His recent publications reflect a strong emphasis on lipid nanoparticles (LNPs), particularly their phase behavior, pH-dependent protonation, and structural transitions relevant to mRNA vaccines. He also explores antimicrobial peptides, membrane domain formation, and the role of cholesterol in modulating membrane properties. His group develops and applies advanced simulation techniques, including constant-pH MD and coarse-grained modeling. Member of Editorial Board, Biophysical Journal (2024–present) Elected Member, DFG Review Board for Biophysics (2020–present) Chairman, Molecular Biophysics Section, German Biophysical Society (2011–2012) Leadership and Service: Böckmann is actively involved in academic governance, serving on editorial boards, DFG committees, and as a guest editor for special issues in Frontiers journals. He contributes to graduate education and high-performance computing initiatives at FAU, including the NHR@FAU and Life@FAU Graduate School. He has organized major conferences and workshops in biophysics and membrane modeling. Laboratory and Collaboration: He leads a research group focused on biomembrane physics, collaborating with experimentalists and theorists. His lab develops and applies simulation tools to study membrane systems, bridging computational insights with biological function.

Olivia Merkelمشاهده پروفایل

استاد

• Drug Delivery
• Pharmaceutical Technology
• Nanomedicine
• +۳ مورد دیگر

Prof. Dr. Olivia Merkel is the Chair of Drug Delivery at LMU Munich (since 2022) and holds a tenured professorship in the Faculty of Pharmacy. Her academic journey includes postdoctoral work at Philipps-Universität Marburg (2009), a PhD in Pharmaceutics (2009), and a tenure-track professorship at Wayne State University (2011–2017). She leads the Merkel Lab, focusing on advanced drug delivery systems, particularly siRNA and nanoparticle-based therapies. Research interests: Nanomedicine, targeted drug delivery, polymer engineering, and pulmonary delivery systems. Editorial roles: Molecular Pharmaceutics, Journal of Controlled Release, and European Journal of Pharmaceutics and Biopharmaceutics. Award: 2020 PHOENIX Pharma Science Award. Her lab combines experimental and computational approaches, with recent work on machine learning-driven polymer discovery and molecular dynamics simulations. Over 20 students and researchers collaborate in her group, addressing challenges in lung fibrosis treatment and T-cell targeting in asthma.

Friedrich Longinمشاهده پروفایل

استاد مدعو

• Plant Breeding
• Wheat Genetics
• Alternative Wheat Varieties
• +۵ مورد دیگر

Dr. Friedrich Longin is an Adjunct Professor and Group Leader of the Wheat Research Group at the State Seed Breeding Institute of the University of Hohenheim, Germany. He leads research on wheat breeding, alternative wheat varieties, and increasing biodiversity in wheat cultivation. University of Hohenheim: Habilitation in Plant Breeding (2016), Adjunct Professor (2019) University of Hohenheim and China Agricultural University in Beijing: Doctorate in a German-Chinese graduate program University of Hohenheim: Studied agricultural biology, specializing in biotechnology and plant breeding Dr. Longin's research focuses on breeding alternative wheat varieties, pre-breeding in wheat, processing and nutritional quality of wheat varieties, nutrient use efficiency in wheat species, and increasing biodiversity and sustainability in wheat cultivation. His breeding research into alternative crops has led to the resurgence of traditional varieties such as spelt, emmer, and einkorn. His work bridges fundamental plant breeding science with practical applications for sustainable agriculture and food systems. He has made significant contributions to understanding the genetic basis of wheat quality traits, disease resistance, and nutritional properties. His recent publications demonstrate a strong focus on genomics-based approaches to wheat improvement, with particular attention to grain quality, nutritional properties, disease resistance, and the relationship between wheat varieties and human health. There is a clear trend toward integrating molecular breeding techniques with traditional approaches, and an increasing emphasis on understanding the health implications of wheat consumption, particularly regarding inflammatory responses and food sensitivities. Active participant in numerous national and international research projects related to wheat breeding and genetic resources Regularly invited to speak at national and international conferences on wheat breeding and sustainable agriculture Volunteers on several professional committees related to plant breeding and agricultural research Dr. Longin heads the Wheat Research Group at the State Seed Breeding Institute of the University of Hohenheim, which focuses on developing improved wheat varieties with enhanced nutritional quality, disease resistance, and environmental adaptability. His team works closely with farmers, millers, and bakers to ensure that new varieties meet the needs of the entire production chain from farm to fork.

Maria Roblesمشاهده پروفایل

استاد

• Chronobiology
• Circadian Rhythms
• Sleep Research
• +۹ مورد دیگر

Prof. Dr. Maria Robles is a full Professor and Head of the Systems Chronobiology research group at the Institute of Medical Psychology, Ludwig-Maximilians-Universität München (LMU), Faculty of Medicine. She leads a dynamic research lab focused on circadian rhythms, sleep, and their molecular underpinnings in health and disease, using cutting-edge quantitative proteomics and mass spectrometry as core methodologies. Her research spans multiple domains, including Circadian regulation of metabolism Molecular mechanisms of sleep and synaptic function Circadian clock dysfunction in diseases such as pancreatic cancer Development of novel proteomic methods (e.g., DIA, multi-omics integration) The analysis of her 15 most recent publications reveals a strong trend toward integrating proteomics with systems biology to dissect temporal dynamics in mammalian tissues. Her work frequently explores post-translational modifications, particularly phosphorylation and ubiquitination, in circadian and sleep contexts, with increasing translational focus on cancer biology and therapeutic targeting. She actively mentors PhD students and postdoctoral researchers, contributing to training the next generation of scientists in chronobiology and proteomics. Her lab is affiliated with the Biomedical Center (BMC) at LMU and is equipped with state-of-the-art instrumentation, including Orbitrap and Q-Exactive mass spectrometers, supported by DFG and LMU funding. She collaborates extensively, notably with Dieter Saur (TUM) on pancreatic cancer research.